vs

Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and Foghorn Therapeutics Inc. (FHTX). Click either name above to swap in a different company.

ASCENT INDUSTRIES CO. is the larger business by last-quarter revenue ($11.9M vs $9.2M, roughly 1.3× Foghorn Therapeutics Inc.). ASCENT INDUSTRIES CO. runs the higher net margin — -8.8% vs -234.3%, a 225.5% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 13.3%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -34.9%).

Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.

ACNT vs FHTX — Head-to-Head

Bigger by revenue
ACNT
ACNT
1.3× larger
ACNT
$11.9M
$9.2M
FHTX
Growing faster (revenue YoY)
FHTX
FHTX
+210.4% gap
FHTX
223.8%
13.3%
ACNT
Higher net margin
ACNT
ACNT
225.5% more per $
ACNT
-8.8%
-234.3%
FHTX
Faster 2-yr revenue CAGR
FHTX
FHTX
Annualised
FHTX
35.3%
-34.9%
ACNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACNT
ACNT
FHTX
FHTX
Revenue
$11.9M
$9.2M
Net Profit
$-1.0M
$-21.7M
Gross Margin
14.6%
Operating Margin
-21.0%
-258.2%
Net Margin
-8.8%
-234.3%
Revenue YoY
13.3%
223.8%
Net Profit YoY
-1.2%
-11.1%
EPS (diluted)
$-0.11
$-0.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACNT
ACNT
FHTX
FHTX
Q4 25
$11.9M
$9.2M
Q3 25
$19.7M
$8.2M
Q2 25
$18.7M
$7.6M
Q1 25
$24.7M
$6.0M
Q4 24
$10.5M
$2.9M
Q3 24
$20.9M
$7.8M
Q2 24
$21.5M
$6.9M
Q1 24
$28.0M
$5.0M
Net Profit
ACNT
ACNT
FHTX
FHTX
Q4 25
$-1.0M
$-21.7M
Q3 25
$-2.1M
$-15.8M
Q2 25
$6.3M
$-17.9M
Q1 25
$-2.3M
$-18.8M
Q4 24
$-1.0M
$-19.5M
Q3 24
$-6.2M
$-19.1M
Q2 24
$-926.0K
$-23.0M
Q1 24
$-5.5M
$-25.0M
Gross Margin
ACNT
ACNT
FHTX
FHTX
Q4 25
14.6%
Q3 25
29.7%
Q2 25
26.1%
Q1 25
19.3%
Q4 24
24.3%
Q3 24
14.4%
Q2 24
13.1%
Q1 24
8.3%
Operating Margin
ACNT
ACNT
FHTX
FHTX
Q4 25
-21.0%
-258.2%
Q3 25
-4.1%
-226.9%
Q2 25
-14.4%
-279.2%
Q1 25
-4.2%
-385.0%
Q4 24
-25.4%
-840.5%
Q3 24
-9.4%
-305.5%
Q2 24
-8.6%
-386.6%
Q1 24
-15.5%
-558.3%
Net Margin
ACNT
ACNT
FHTX
FHTX
Q4 25
-8.8%
-234.3%
Q3 25
-10.6%
-194.4%
Q2 25
33.7%
-237.3%
Q1 25
-9.3%
-316.4%
Q4 24
-9.8%
-682.9%
Q3 24
-29.5%
-244.9%
Q2 24
-4.3%
-333.6%
Q1 24
-19.7%
-495.4%
EPS (diluted)
ACNT
ACNT
FHTX
FHTX
Q4 25
$-0.11
$-0.35
Q3 25
$-0.22
$-0.25
Q2 25
$0.65
$-0.28
Q1 25
$-0.23
$-0.30
Q4 24
$-0.11
$-0.23
Q3 24
$-0.61
$-0.31
Q2 24
$-0.09
$-0.45
Q1 24
$-0.54
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACNT
ACNT
FHTX
FHTX
Cash + ST InvestmentsLiquidity on hand
$57.6M
$80.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$87.0M
$-108.5M
Total Assets
$111.9M
$198.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACNT
ACNT
FHTX
FHTX
Q4 25
$57.6M
$80.9M
Q3 25
$58.0M
$89.3M
Q2 25
$60.5M
$72.6M
Q1 25
$14.3M
$61.0M
Q4 24
$16.1M
$55.5M
Q3 24
$8.5M
$57.7M
Q2 24
$3.6M
$138.9M
Q1 24
$1.3M
$79.3M
Total Debt
ACNT
ACNT
FHTX
FHTX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACNT
ACNT
FHTX
FHTX
Q4 25
$87.0M
$-108.5M
Q3 25
$87.1M
$-89.7M
Q2 25
$89.7M
$-76.7M
Q1 25
$91.2M
$-61.7M
Q4 24
$93.5M
$-45.5M
Q3 24
$94.7M
$-28.3M
Q2 24
$101.0M
$-14.3M
Q1 24
$102.0M
$-97.5M
Total Assets
ACNT
ACNT
FHTX
FHTX
Q4 25
$111.9M
$198.1M
Q3 25
$119.9M
$205.0M
Q2 25
$122.6M
$226.2M
Q1 25
$152.5M
$258.7M
Q4 24
$147.3M
$284.0M
Q3 24
$148.6M
$308.4M
Q2 24
$158.2M
$328.6M
Q1 24
$161.0M
$255.0M
Debt / Equity
ACNT
ACNT
FHTX
FHTX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACNT
ACNT
FHTX
FHTX
Operating Cash FlowLast quarter
$266.0K
$-22.3M
Free Cash FlowOCF − Capex
$-196.0K
FCF MarginFCF / Revenue
-1.7%
Capex IntensityCapex / Revenue
3.9%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-2.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACNT
ACNT
FHTX
FHTX
Q4 25
$266.0K
$-22.3M
Q3 25
$1.3M
$-18.9M
Q2 25
$-1.4M
$-21.0M
Q1 25
$-700.0K
$-24.0M
Q4 24
$8.8M
$-24.5M
Q3 24
$3.4M
$-21.0M
Q2 24
$2.2M
$-25.5M
Q1 24
$263.0K
$-29.3M
Free Cash Flow
ACNT
ACNT
FHTX
FHTX
Q4 25
$-196.0K
Q3 25
$695.0K
Q2 25
$-1.5M
$-21.0M
Q1 25
$-1.0M
$-24.0M
Q4 24
$8.4M
$-25.0M
Q3 24
$3.1M
$-21.3M
Q2 24
$1.9M
$-25.6M
Q1 24
$25.0K
$-29.4M
FCF Margin
ACNT
ACNT
FHTX
FHTX
Q4 25
-1.7%
Q3 25
3.5%
Q2 25
-8.3%
-278.2%
Q1 25
-4.1%
-403.2%
Q4 24
80.6%
-875.3%
Q3 24
15.1%
-273.0%
Q2 24
9.1%
-371.0%
Q1 24
0.1%
-583.1%
Capex Intensity
ACNT
ACNT
FHTX
FHTX
Q4 25
3.9%
0.0%
Q3 25
3.1%
0.0%
Q2 25
0.8%
0.3%
Q1 25
1.3%
0.5%
Q4 24
3.7%
16.8%
Q3 24
1.3%
4.0%
Q2 24
1.0%
0.2%
Q1 24
0.9%
2.0%
Cash Conversion
ACNT
ACNT
FHTX
FHTX
Q4 25
Q3 25
Q2 25
-0.22×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACNT
ACNT

Other$6.1M52%
Transferred At Point In Time$5.7M48%

FHTX
FHTX

Segment breakdown not available.

Related Comparisons